The 22-kDa antigen in optic nerve and retinal diseases

Journal of Neuro-Ophthalmology

Volumn 19, Issue 2, 1999, Pages 71-83

  Keltner, John L ^a   Thirkill, Charles E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

22 kDa Antigen; Autoantibody; Non cancer associated retinopathy; Optic neuropathy; Retinopathy

Indexed keywords

EID: 84975517841     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/00041327-199906000-00001     Document Type: Article

References (50)

1. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal cancer-associated retinopathy antigen. Arch Ophthalmol 1993;111: 974-8.
2. Thirkill CE, Tait RC, Tyler NK, Roth AM Keltner JL. The Cancer connection: An antigen immunologically related to the retinal CAR antigen is expressed in small cell carcinoma of the lung. In: J.P.Dernouchamps, ed. Proceedings of the Third International Symposium on Uveitis. Amsterdam: Kugler Publications 1993;133-5.
3. Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol 1983;101: 564-9.
4. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol 1987;105: 372-5.
5. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 1976;81: 606-13.
6. Kornguth SE. Neuronal proteins and paraneoplastic syndromes. N EnglJMed 1989;321: 1607-8.
7. Kornguth SE, Klein R, Appen R, Choate J. Occurrence of anti-retinal ganglion cell antibodies in patients with small cell carcinoma of the lung. Cancer 1982;50: 1289-93.
8. Kornguth SE, Kalinke T, Grunwald GB, Schutta H, Dahl D. Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome. Cancer Res 1986;46: 2588-95.
9. Klingele TG, Bürde RM, Rappazzo JA, Isserman MJ, Burgess D, Kantor O. Paraneoplastic retinopathy. J Clin Neuro-Ophthalmol 1984;4: 239-45.
10. Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 1989;321: 1589-94.
11. Thirkill CE, Roth AM, Keltner JL. Paraneoplastic retinopathy syndrome. Ophthalmology 1993;100: 147.
12. Thirkill CE, Keltner JL, Tyler NK, Roth AM. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol 1993;111: 931-7.
13. Cogan DG, Kuwabara T, Currie J, Kattah J. Paraneoplastic retinopathy simulating cone dystrophy with achromatopsia. Klin Monatsbl Augenheilkd 1990;197: 156-8.
14. Jacobson DM, Thirkill CE. Paraneoplastic cone dysfunction: An unusual visual remote effect of cancer. Arch Ophthalmol 1996;113: 1580-2.
15. Anderson NE. Paraneoplastic optic neuritis and external ophthalmoplegia. Aust N Z 1987;17: 539.
16. Sergott RC, Brown MJ, Silberberg DH, Lisak RP. Antigalactocer-ebroside serum demyelinates optic nerve in vivo. Neurol Sei 1984;64: 297-303.
17. Boghen DR, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Arch Neurol 1988;45: 353-6.
18. Thirkill CE. Cancer Associated Retinopathy, The CAR Syndrome. Neuro-Ophthalmology 1994;14: 297-323.
19. Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer associated retinopathy (CAR). Arch Ophthalmol 1992;110: 48-53.
20. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. The Cancer-Associated Retinopathy is a recoverin-like protein. Invest Ophthalmol Vis Sci 1992;331: 2768-72.
21. Jacobson DM, Thirkill CE, Tipping SJ. A clinical trial to diagnose paraneoplastic retinopathy. Ann Neurol 1990;28: 162-7.
22. Hooper PL Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology 1991;98: 944-52.
23. Weinstein J, Bresnick G, Kornguth SE. Paraneoplastic retinopathy associated with anti-retinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 1994;101: 1236-43.
24. Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MO. ‘On’ response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci 1992;33: 477-83.
25. Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988;106: 307-11.
26. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993;34: 91-100.
27. Okel BB, Thirkill CE, Anderson K. An unusual case of melanoma-associated retinopathy. Ocular Immunol Inflamm 1995;3: 121-7.
28. Mizener JB, Kimura AE, Adamus G, Thirkill C, Goeken JA, Kar-don RH. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol 1997;123: 607-18.
29. Heckenlively JR, Oversier JJ, Jordan B, Aptsiauri N. CAR-like syndrome: Progressive panretinal degenerations not associated with cancer but with anti-recoverin (and other) anti-retinal antibodies (abstract 997). Invest Ophthalmol Vis Sci 1998;39: S216.
30. Aptsiauri N, Jordan BI, Heckenlively J. Anti-recoverin immuno-reactivity in patients with retinal degeneration without systemic malignancy (abstract 1694). Invest Ophthalmol Vis Sci 1998;39: S363.
31. Whitcup SM, Vistica BP, Milam AH et al. Recoverin-associated retinopathy: A clinically and immunologically distinctive disease. Am J Ophthalmol 1998;126: 230-7.
32. Keltner JL, Thirkill CE. Cancer associated retinopathy vs. recov-erin associated retinopathy. Am J Ophthalmol 1998;126: 296-302.
33. Peek R, Verbraak F, Coevoet HMN, Kijlstra A. Muller cell-specific autoantibodies in a patient with progressive loss of vision. Invest Ophthalmol Vis Sci 1998;39: 1976-7.
34. Kumar M, Gupta RM, Nema HV. Role of autoimmunity in retinitis pigmentosa. Ann Ophthalmol 1983;15: 838-40.
35. Chant SM, Heckenlively JR, Meyers-Elliott RH. Autoimmunity in hereditary retinal degeneration, I: basic studies. Br J Ophthalmol 1985;69: 758-64.
36. Thirkill CE, Roth AM, Takemoto DJ, Tyler NK, Keltner JL. Antibody indications of secondary and superimposed retinal hypersensitivity in retinitis pigmentosa. Am J Ophthalmol 1991;1121: 132-7.
37. Gurne DH, Tso MOM, Edward DP, Ripps H. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology 1991;98: 602-7.
38. Isashiki Y, Ohba N, Nakagawa M, Miyake Y. Antibodies against human retinal proteins in serum from patients with cone dystrophy. Jpn J Ophthalmol 1992;36: 323-30.
39. Oksaranta O, Tarvonen S, Honen J, et al. T-cell subpopulations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: a follow-up study. Neurology 1996;47: 1542-5.
40. Paty DW, Li DKB, the UBC MS/MRI Study Group, IFN-B Multiple Sclerosis Study Group. Interferon B-lb is effective in relaps-ing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655-61.
41. Hohlfeld R, Meinl E, Weber F, et al. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 1995;45(suppl 6): S33-8.
42. Lisak RP. Overview of the rationale for immunomodulating therapies in multiple sclerosis. Neurology 1988;38(suppl): 5-8.
43. Sergott RC, Brown MJ, Polenta RM, Lisak RP, Silberberg DH. Optic nerve demyelination induced by human serum: Patients with multiple sclerosis or optic neuritis and normal subjects. Neurology 1985;35: 1438-42.
44. Anderson NE, Cunningham JM, Posner JB. Autoimmune pathogenesis of paraneoplastic neurological syndromes. Crit Rev Neu-robiol 1987;3: 245-99.
45. Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol 1988;45: 353-6.
46. Luiz JE, Lee AG, Keltner JL, Thirkill CE, Lai EC. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuro-Ophthalmol 1998;18: 178-81.
47. Milam AH, Dacey DM, Dizhoor AM. Recoverin immunoreactivity in mammalian cone bipolar cells. Vis Neurosci 1993;10: 1-12.
48. Igal G, Chanaud NP, Anglade E. Recoverin is highly uveitogenic in Lewis rats. Invest Ophthalmol Vis Sci 1994;35: 3342-5.
49. Polans AS, Burton MD, Halet TL, Crabb JW, Palczewski K. Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 1993;34: 81-90.
50. Thirkill CE. Retinal antibodies. In: Peter JB, Shoenfeld Y, eds. Autoantibodies. The Netherlands: Elsevier, 1996: 694-9.